Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siERBB3
- Development stage
- Preclinical
- Lead developer
- University of Pittsburgh
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
siERBB3 is a small interfering RNA (siRNA) designed to target and silence the expression of receptor tyrosine-protein kinase erbB-3 (ERBB3/HER3). Developed by researchers at the University of Pittsburgh, siERBB3 is formulated within lipid nanoparticles (LNPs) for in vivo delivery. In preclinical models of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), therapeutic silencing of hepatocyte ERBB3 via LNP-delivered siERBB3 has been shown to reverse established steatosis and fibrosis. Mechanistically, ERBB3 knockdown attenuates downstream PI3K-AKT-mTOR signaling, suppresses PPAR-gamma, and restores HNF4-alpha expression, thereby reprogramming the metabolic PPAR-gamma-HNF4-alpha axis to restore hepatic homeostasis and induce lipophagy.
- Other names
- ERBB3 siRNAERBB-3 siRNAERBB 3 siRNAHER3 siRNAHER-3 siRNAHER 3 siRNAsiErbB3siErbB-3siErbB 3
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on siERBB3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siERBB3.